RU2398566C2 - Применение вязкоупругой композиции по новому назначению - Google Patents
Применение вязкоупругой композиции по новому назначению Download PDFInfo
- Publication number
- RU2398566C2 RU2398566C2 RU2006142861/15A RU2006142861A RU2398566C2 RU 2398566 C2 RU2398566 C2 RU 2398566C2 RU 2006142861/15 A RU2006142861/15 A RU 2006142861/15A RU 2006142861 A RU2006142861 A RU 2006142861A RU 2398566 C2 RU2398566 C2 RU 2398566C2
- Authority
- RU
- Russia
- Prior art keywords
- fistula
- eye
- present
- viscoelastic
- sclera
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title description 24
- 206010016717 Fistula Diseases 0.000 claims abstract description 116
- 230000003890 fistula Effects 0.000 claims abstract description 116
- 238000000034 method Methods 0.000 claims abstract description 66
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 38
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 38
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 38
- 241001465754 Metazoa Species 0.000 claims abstract description 26
- 230000000149 penetrating effect Effects 0.000 claims abstract description 26
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 16
- 210000001508 eye Anatomy 0.000 claims description 58
- 210000003786 sclera Anatomy 0.000 claims description 50
- 230000004410 intraocular pressure Effects 0.000 claims description 28
- 239000007863 gel particle Substances 0.000 claims description 26
- 208000010412 Glaucoma Diseases 0.000 claims description 18
- 239000007924 injection Substances 0.000 claims description 18
- 238000002347 injection Methods 0.000 claims description 18
- 210000002159 anterior chamber Anatomy 0.000 claims description 16
- 210000004127 vitreous body Anatomy 0.000 claims description 5
- 239000003814 drug Substances 0.000 abstract description 13
- 239000000126 substance Substances 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- 230000002085 persistent effect Effects 0.000 abstract description 2
- 206010030043 Ocular hypertension Diseases 0.000 abstract 2
- 150000004676 glycans Chemical class 0.000 description 23
- 229920001282 polysaccharide Polymers 0.000 description 22
- 239000005017 polysaccharide Substances 0.000 description 22
- 210000000795 conjunctiva Anatomy 0.000 description 20
- 239000000499 gel Substances 0.000 description 18
- 238000001356 surgical procedure Methods 0.000 description 17
- 239000002245 particle Substances 0.000 description 15
- 238000011282 treatment Methods 0.000 description 14
- 210000001742 aqueous humor Anatomy 0.000 description 11
- 230000035515 penetration Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 230000035876 healing Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 239000003431 cross linking reagent Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000004132 cross linking Methods 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000003190 viscoelastic substance Substances 0.000 description 6
- 210000004087 cornea Anatomy 0.000 description 5
- 230000004962 physiological condition Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000037390 scarring Effects 0.000 description 4
- 241001631457 Cannula Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 210000001328 optic nerve Anatomy 0.000 description 3
- 229940006076 viscoelastic substance Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 229920001605 Dextranomer Polymers 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000018866 Hyaluronan Receptors Human genes 0.000 description 2
- 108010013214 Hyaluronan Receptors Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 210000003161 choroid Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 229960002864 dextranomer Drugs 0.000 description 2
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical class C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000004898 kneading Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 230000036573 scar formation Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241001481048 Eguchipsammia fistula Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical class C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000004493 normal intraocular pressure Effects 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Liquid Crystal (AREA)
- Liquid Crystal Display Device Control (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0401182A SE0401182D0 (sv) | 2004-05-05 | 2004-05-05 | Novel use of a viscoelastic composition |
| SE0401182-1 | 2004-05-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006142861A RU2006142861A (ru) | 2008-06-20 |
| RU2398566C2 true RU2398566C2 (ru) | 2010-09-10 |
Family
ID=32466229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006142861/15A RU2398566C2 (ru) | 2004-05-05 | 2005-05-04 | Применение вязкоупругой композиции по новому назначению |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8721622B2 (enExample) |
| EP (1) | EP1796624B1 (enExample) |
| JP (1) | JP4922158B2 (enExample) |
| AT (1) | ATE506940T1 (enExample) |
| AU (1) | AU2005237394B2 (enExample) |
| CA (1) | CA2565382C (enExample) |
| DE (1) | DE602005027718D1 (enExample) |
| ES (1) | ES2365621T3 (enExample) |
| MX (1) | MXPA06012615A (enExample) |
| RU (1) | RU2398566C2 (enExample) |
| SE (1) | SE0401182D0 (enExample) |
| WO (1) | WO2005105037A2 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2432141C1 (ru) * | 2010-08-30 | 2011-10-27 | Александр Геннадьевич Савенков | Применение ирригационной жидкости в офтальмохирургии |
| RU2460517C1 (ru) * | 2011-07-14 | 2012-09-10 | Федеральное государственное учреждение "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" | Фармацевтическая композиция для комплексного лечения заболеваний глазной поверхности у больных с первичной открытоугольной глаукомой |
| RU2568998C2 (ru) * | 2013-03-27 | 2015-11-20 | ЭлДжи ЛАЙФ САЙЕНСИЗ ЛТД. | Композиция для получения сшитой гиалуроновой кислоты и способ получения сшитой гиалуроновой кислоты |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7909789B2 (en) | 2006-06-26 | 2011-03-22 | Sight Sciences, Inc. | Intraocular implants and methods and kits therefor |
| JP5694664B2 (ja) * | 2006-09-29 | 2015-04-01 | サーモディクス，インコーポレイティド | 生分解性眼用インプラント及び眼の病気を治療する方法 |
| US8703119B2 (en) | 2007-10-05 | 2014-04-22 | Polygene Ltd. | Injectable biodegradable polymer compositions for soft tissue repair and augmentation |
| US8083720B2 (en) * | 2008-05-13 | 2011-12-27 | Solar Matthew S | Device and method for delivering therapeutic agents to an area of the body |
| US9339514B2 (en) * | 2008-09-12 | 2016-05-17 | Aptissen Sa | Method for treating glaucoma |
| US8715266B2 (en) * | 2008-09-12 | 2014-05-06 | Aptissen Sa | Glaucoma surgery |
| CN102405049A (zh) * | 2009-02-19 | 2012-04-04 | 帝人株式会社 | 多糖类衍生物的水凝胶 |
| US8529622B2 (en) | 2010-02-05 | 2013-09-10 | Sight Sciences, Inc. | Intraocular implants and related kits and methods |
| US8574217B2 (en) | 2010-04-08 | 2013-11-05 | Kmg Pharma, Llc | Sub-mucosal agent delivery method for the eye |
| US8652118B2 (en) | 2010-04-08 | 2014-02-18 | Kmg Pharma, Llc | Sub-mucosal agent delivery, apparatus, system and method |
| US8430862B2 (en) * | 2010-04-08 | 2013-04-30 | KMG Pharma LLC | Subconjunctival agent delivery apparatus, system and method |
| US9216109B2 (en) | 2012-03-20 | 2015-12-22 | Sight Sciences, Inc. | Ocular delivery systems and methods |
| US9782247B2 (en) * | 2014-02-18 | 2017-10-10 | Cook Medical Technologies, LLC | Flexible embolic double filter |
| US10299958B2 (en) | 2015-03-31 | 2019-05-28 | Sight Sciences, Inc. | Ocular delivery systems and methods |
| CN110621320B (zh) | 2017-05-17 | 2023-03-17 | Tx医生公司 | 青光眼的治疗 |
| WO2019229719A1 (en) * | 2018-06-01 | 2019-12-05 | Sun Pharma Advanced Research Company Limited | An injection device |
| US11504270B1 (en) | 2019-09-27 | 2022-11-22 | Sight Sciences, Inc. | Ocular delivery systems and methods |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4716154A (en) * | 1984-06-08 | 1987-12-29 | Pharmacia Ab | Gel of crosslinked hyaluronic acid for use as a vitreous humor substitute |
| WO1992000745A1 (en) * | 1990-07-03 | 1992-01-23 | Autogenesis Technologies, Inc. | Collagen-based viscoelastic solution for visco-surgery |
| US5360399A (en) * | 1992-01-10 | 1994-11-01 | Robert Stegmann | Method and apparatus for maintaining the normal intraocular pressure |
| US5360425A (en) * | 1990-08-17 | 1994-11-01 | Candela Laser Corporation | Sclerostomy method and apparatus |
| US5827937A (en) * | 1995-07-17 | 1998-10-27 | Q Med Ab | Polysaccharide gel composition |
| RU2207845C2 (ru) * | 1996-12-02 | 2003-07-10 | Сосьете Де Консей Де Решерш Э Дапликасьон Сьянтифик Скрас | Твердая лекарственная форма пролонгированного действия для парентерального введения и способ ее получения |
| US20030211166A1 (en) * | 2001-07-31 | 2003-11-13 | Yamamoto Ronald K | Microparticulate biomaterial composition for medical use |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2774239A (en) | 1952-07-26 | 1956-12-18 | Wisconsin Alumni Res Found | Apparatus for determining dynamic mechanical properties of viscoelastic materials |
| US4965253A (en) * | 1987-10-14 | 1990-10-23 | University Of Florida | Viscoelastic material for ophthalmic surgery |
| US5066276A (en) * | 1988-06-21 | 1991-11-19 | Alcon Laboratories, Inc. | Method and apparatus for injecting viscous fluid into the eye to lift pre-retinal and post-retinal membrane with linear pressure control |
| US4955883A (en) | 1988-08-29 | 1990-09-11 | Diversatronics | Glaucoma needle with a thermal heat band |
| US5092837A (en) | 1989-12-20 | 1992-03-03 | Robert Ritch | Method for the treatment of glaucoma |
| US5273056A (en) * | 1992-06-12 | 1993-12-28 | Alcon Laboratories, Inc. | Use of combinations of viscoelastics during surgery |
| US5707643A (en) * | 1993-02-26 | 1998-01-13 | Santen Pharmaceutical Co., Ltd. | Biodegradable scleral plug |
| US5811453A (en) | 1994-12-23 | 1998-09-22 | Alcon Laboratories, Inc. | Viscoelastic compositions and methods of use |
| US6142969A (en) | 1996-10-25 | 2000-11-07 | Anamed, Inc. | Sutureless implantable device and method for treatment of glaucoma |
| US20020111603A1 (en) | 1996-12-02 | 2002-08-15 | Societe De Conseils De Recherches Et D'application | Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process |
| FR2759577B1 (fr) | 1997-02-17 | 1999-08-06 | Corneal Ind | Implant de sclerectomie profonde |
| US6495608B1 (en) | 1997-07-29 | 2002-12-17 | Alcon Manufacturing, Ltd. | Methods of performing surgery with galactomannan polymers and borate |
| US6378526B1 (en) * | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
| US6635267B1 (en) | 1998-11-10 | 2003-10-21 | Denki Kagaku Kogyo Kabushiki Kaisha | Hyaluronic acid gel, process for the preparation thereof and medical materials containing the same |
| ES2311455T3 (es) * | 1999-04-02 | 2009-02-16 | Fziomed, Inc. | Composiciones de poliacidos, de polimeros no ionicos de monomeros de oxido de alquileno y cationes multivalentes y su utilizacion para la reduccion de adherencias. |
| US6558342B1 (en) | 1999-06-02 | 2003-05-06 | Optonol Ltd. | Flow control device, introducer and method of implanting |
| CA2393673A1 (en) * | 1999-12-10 | 2001-06-14 | Iscience Corporation | Treatment of ocular disease |
| US6375642B1 (en) | 2000-02-15 | 2002-04-23 | Grieshaber & Co. Ag Schaffhausen | Method of and device for improving a drainage of aqueous humor within the eye |
| US6638239B1 (en) * | 2000-04-14 | 2003-10-28 | Glaukos Corporation | Apparatus and method for treating glaucoma |
| EP1305057B1 (en) * | 2000-07-31 | 2005-06-22 | Iscience Corporation | Microparticulate biomaterial composition of hyaluronic acid for medical use |
| FR2819722B1 (fr) * | 2001-01-19 | 2006-11-24 | Corneal Ind | Utilisation de l'acide hyaluronique ou d'au moins l'un de ses sels dans le cadre d'un traitemnet chirurgical de la presbytie |
| EP1539066B1 (en) * | 2002-09-17 | 2012-11-07 | Iscience Surgical Corporation | Apparatus surgical bypass of aqueous humor |
-
2004
- 2004-05-05 SE SE0401182A patent/SE0401182D0/xx unknown
-
2005
- 2005-05-04 EP EP05740578A patent/EP1796624B1/en not_active Expired - Lifetime
- 2005-05-04 AU AU2005237394A patent/AU2005237394B2/en not_active Ceased
- 2005-05-04 MX MXPA06012615A patent/MXPA06012615A/es active IP Right Grant
- 2005-05-04 CA CA2565382A patent/CA2565382C/en not_active Expired - Lifetime
- 2005-05-04 US US11/579,621 patent/US8721622B2/en active Active
- 2005-05-04 WO PCT/SE2005/000663 patent/WO2005105037A2/en not_active Ceased
- 2005-05-04 DE DE602005027718T patent/DE602005027718D1/de not_active Expired - Lifetime
- 2005-05-04 ES ES05740578T patent/ES2365621T3/es not_active Expired - Lifetime
- 2005-05-04 AT AT05740578T patent/ATE506940T1/de not_active IP Right Cessation
- 2005-05-04 JP JP2007511320A patent/JP4922158B2/ja not_active Expired - Fee Related
- 2005-05-04 RU RU2006142861/15A patent/RU2398566C2/ru active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4716154A (en) * | 1984-06-08 | 1987-12-29 | Pharmacia Ab | Gel of crosslinked hyaluronic acid for use as a vitreous humor substitute |
| WO1992000745A1 (en) * | 1990-07-03 | 1992-01-23 | Autogenesis Technologies, Inc. | Collagen-based viscoelastic solution for visco-surgery |
| US5360425A (en) * | 1990-08-17 | 1994-11-01 | Candela Laser Corporation | Sclerostomy method and apparatus |
| US5360399A (en) * | 1992-01-10 | 1994-11-01 | Robert Stegmann | Method and apparatus for maintaining the normal intraocular pressure |
| US5827937A (en) * | 1995-07-17 | 1998-10-27 | Q Med Ab | Polysaccharide gel composition |
| RU2207845C2 (ru) * | 1996-12-02 | 2003-07-10 | Сосьете Де Консей Де Решерш Э Дапликасьон Сьянтифик Скрас | Твердая лекарственная форма пролонгированного действия для парентерального введения и способ ее получения |
| US20030211166A1 (en) * | 2001-07-31 | 2003-11-13 | Yamamoto Ronald K | Microparticulate biomaterial composition for medical use |
Non-Patent Citations (1)
| Title |
|---|
| RAITTA С. at al. Effect of intracamerally or subconjunctivally injected cross-linked hualuronic acid on the intraocular pressure and on the anterior segment of the rabbit eye. Acta Ophthalmol(Copenh), 1988 Oct; 66(5):544-51. * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2432141C1 (ru) * | 2010-08-30 | 2011-10-27 | Александр Геннадьевич Савенков | Применение ирригационной жидкости в офтальмохирургии |
| RU2460517C1 (ru) * | 2011-07-14 | 2012-09-10 | Федеральное государственное учреждение "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" | Фармацевтическая композиция для комплексного лечения заболеваний глазной поверхности у больных с первичной открытоугольной глаукомой |
| RU2568998C2 (ru) * | 2013-03-27 | 2015-11-20 | ЭлДжи ЛАЙФ САЙЕНСИЗ ЛТД. | Композиция для получения сшитой гиалуроновой кислоты и способ получения сшитой гиалуроновой кислоты |
Also Published As
| Publication number | Publication date |
|---|---|
| US20080058760A1 (en) | 2008-03-06 |
| WO2005105037A2 (en) | 2005-11-10 |
| EP1796624A2 (en) | 2007-06-20 |
| SE0401182D0 (sv) | 2004-05-05 |
| CA2565382A1 (en) | 2005-11-10 |
| EP1796624B1 (en) | 2011-04-27 |
| DE602005027718D1 (de) | 2011-06-09 |
| ES2365621T3 (es) | 2011-10-07 |
| WO2005105037A3 (en) | 2006-05-18 |
| CA2565382C (en) | 2013-12-03 |
| ATE506940T1 (de) | 2011-05-15 |
| RU2006142861A (ru) | 2008-06-20 |
| AU2005237394A1 (en) | 2005-11-10 |
| WO2005105037A8 (en) | 2006-12-21 |
| JP2007536220A (ja) | 2007-12-13 |
| JP4922158B2 (ja) | 2012-04-25 |
| AU2005237394B2 (en) | 2009-12-10 |
| US8721622B2 (en) | 2014-05-13 |
| MXPA06012615A (es) | 2007-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2565382C (en) | Use of a viscoelastic composition for treating increased intraocular pressure | |
| US20050277864A1 (en) | Injectable gel implant for glaucoma treatment | |
| KR100478355B1 (ko) | 안압을 저하시키는 기구 | |
| AU2001245522C1 (en) | Apparatus and method for treating glaucoma | |
| US20030229303A1 (en) | Expandable glaucoma implant and methods of use | |
| AU2014238174B2 (en) | Trans-sclera portal for delivery of therapeutic agents | |
| US8715266B2 (en) | Glaucoma surgery | |
| US9339514B2 (en) | Method for treating glaucoma | |
| EP1023077A1 (en) | Opthalmic composition | |
| Hoopes | Sodium hyaluronate (Healon®) in anterior segment surgery: A review and a new use in extracapsular surgery | |
| EP4149400B1 (en) | Methods and compositions for reducing intraocular pressure | |
| RU2297815C1 (ru) | Способ хирургического лечения рефракторных глауком | |
| RU2284181C2 (ru) | Фармацевтическая композиция для профилактики инфекции в офтальмологии "интрависк" | |
| RU2297816C1 (ru) | Способ хирургического лечения рефрактерных глауком | |
| RU2239399C1 (ru) | Дренаж для лечения неоваскулярной глаукомы и способ лечения неоваскулярной глаукомы | |
| RU2228160C2 (ru) | Способ лечения рецидивирующей цилиохориоидальной отслойки после антиглаукоматозной операции | |
| Refojo | Materials for use in the eye | |
| RU2362525C1 (ru) | Способ лечения рефрактерной закрытоугольной глаукомы | |
| Pandya et al. | Experimental evaluation of a hydroxylapatite reservoir tube shunt in rabbits | |
| Schnyder et al. | Implants in non-penetrating filtering surgery | |
| RU2585728C1 (ru) | Дренаж для офтальмологических операций | |
| RU2557925C1 (ru) | Биодеградируемый многослойный имплант для введения лекарственных веществ в витреальную полость глаза | |
| WO1992018163A1 (en) | Medicine for intraocular operation | |
| DEEP | Dida Kazakova¹ 23*, Andre Mermoud and Gunther Krieglstein3 | |
| Machemer | One of the most exciting developments in ophthalmology is taking place in an area that formerly received little attention. For years, most surgeons dreaded the disasters likely to occur after initially successful retinal surgery. It is only over the last 10 years or so that the problem of |